StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Research analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

MRNS has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.55 on Monday. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $9.69. The business has a 50-day moving average of $0.54 and a 200 day moving average of $0.80. The stock has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 126,752 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares in the last quarter. Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals during the 4th quarter valued at approximately $107,000. Jacobs Levy Equity Management Inc. increased its position in Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after buying an additional 117,255 shares in the last quarter. Finally, Suvretta Capital Management LLC increased its position in Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.